miRoncol Health
Booth 6 A
A miracle in oncology powered by miRNA
miRoncol Health is democratizing preventative healthcare with an AI-powered blood test starting from enabling more cancer early detection based on microRNAs, the 2024 Nobel-recognized discovery. miRoncol published the first-of-its-kind multi-cancer early detection model based on its proof-of-concept studies. It achieved about 90% sensitivity at >99% specificity across 10+ common solid tumors responsible for ~80% cancers except breast cancer. Leveraging existing blood test infrastructure and equipment, miRoncol Health brings an affordable and accurate category-defining solution to enable more cancer early detection to save more lives.